REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemi
Go back to REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemi| Jennison Natural Resources Fund Class B (NASDAQ: RGNX) | Delayed: 8.07 -0.15 (1.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.22 | 52 Week High | $25.00 | |||
| Open | $8.22 | 52 Week Low | $7.07 | |||
| Day High | $8.33 | P/E | N/A | |||
| Day Low | $8.05 | EPS | $0.00 | |||
| Volume | 494,801 | |||||
